Chinese Journal of Pharmacovigilance ›› 2022, Vol. 19 ›› Issue (1): 72-73.
DOI: 10.19803/j.1672-8629.2022.01.15

Previous Articles     Next Articles

Efficacy of chemotherapy combined with anlotinib against advanced pancreatic cancer

XU Baoyu1,2, SHEN Hua3, LI Xin1,*, HAN Feng1,*   

  1. 1School of Pharmacy, Nanjing Medical University, Nanjing Jiangsu 211166, China;
    2Depar-tment of Human Anatomy, School of Basic Medical Sciences, Nanjing Medical University, Nanjing Jiangsu 211166, China;
    3Sir Run Run Hospital, Nanjing Medical University, Nanjing Jingsu 211166, China
  • Received:2021-04-30 Online:2022-01-15 Published:2022-01-20

PDF (PC)

121

Abstract: Objective To investigate the efficacy of chemotherapy combined with anlotinib in treating advanced pancreatic cancer. Methods The clinical data on 60 patients with advanced pancreatic cancer was retrospectively analyzed who had been treated at Yifu Hospital and Hai'an People's Hospital between October 31, 2019 and February 28, 2021. The patients were divided into a control group and a test group using the random number table method, with 30 in each group. Patients in the control group were treated with single-agent gemcitabine while those in the experimental group were treated with albumin-bound paclitaxel and gemcitabine as the main chemotherapy combined with anlotinib. The overall survival and incidence of adverse reactions were observed. Results Chemotherapy combined with anlotinib prolonged the survival of patients with advanced pancreatic cancer. Conclusion Chemotherapy combined with anlotinib can improve the therapeutic effect against advanced pancreatic cancer.

Key words: pancreatic cancer, gemcitabiner, albumin-bound paclitaxel, anlotinib

CLC Number: